Lapatinib Completed Phase 2 Trials for Cancer, Breast / Metastatic Breast Cancer (MBC) Treatment

CompletedTreatment2 IdentifierTitleDrugs
NCT00404066Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer
NCT02338245Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab
NCT00694252Lapatinib and Circulating Tumor Cells in Breast Cancer
NCT00841828Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
NCT01485926A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.
NCT01973660PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer
NCT00548184Lapatinib and Trastuzumab With or Without Endocrine Therapy
NCT01275859Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast Cancer
NCT00721630Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer
NCT00482391Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
NCT01068704Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
NCT00769470Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery
NCT00299286Short-term Presurgical Study to Assess Molecular Predictors of Lapatinib's Effects in Primary Breast Cancer
NCT00206427Neoadjuvant GW572016 to Treat Breast Cancer